PTC Therapeutics, Inc. Preferred Stock (Total)

Preferred Stock (Total) of PTCT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Preferred Stock (Total) growth rates and interactive chart.


Highlights and Quick Summary

  • Preferred Stock (Total) for the quarter ending March 30, 2013 was $158 Million (a 95.66% increase compared to previous quarter)
  • Year-over-year quarterly Preferred Stock (Total) increased by Infinity%
  • Annual Preferred Stock (Total) for 2012 was $80.8 Million (a -62.3% decrease from previous year)
Visit stockrow.com/PTCT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Preferred Stock (Total) of PTC Therapeutics, Inc.

Most recent Preferred Stock (Total)of PTCT including historical data for past 10 years.

Interactive Chart of Preferred Stock (Total) of PTC Therapeutics, Inc.

PTC Therapeutics, Inc. Preferred Stock (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2013 $158.14
2012 $80.82 $0.0 $0.0 $0.0 $80.82
2011 $214.37 $214.38

Business Profile of PTC Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.